Figure 1

Immunohistochemical staining of pVEGFR-1 in tumor cells and VEGFR-1 in inflammatory cells of CC tissue. (A) Characteristic pVEGFR-1^Tyr1048 expression in tumor cells with membranous and cytoplasmic immunostaining (x 400). (B) Characteristic pVEGFR-1^Tyr1213 expression in tumor cells with membranous and cytoplasmic immunostaining (x 400). (C) Characteristic pVEGFR-1^Tyr1333 expression in tumor cells with nuclear immunostaining (x 400). (D) pVEGFR-1 expression in tumor cells in tumor budding regions. Tumor budding was defined as single tumor cells and oligocellular tumor cell clusters along the invasive margin (D1, H.E., x 200). Expression of pVEGFR-1^Tyr1048 (D2, x 200) and pVEGFR-1^Tyr1213 (D3, x 200) in tumor budding regions. (E) Characteristic VEGFR-1 expression in inflammatory cells. Lymph follicles along the invasive front (E1, H.E., x 40) with VEGFR-1 immunopositivity (E2, x 100) in a non-metastatic CC case.